Daiichi Buys Biotech Antibody Technology From U.S. Firm
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo bought compound-combining technology from Seattle Genetics, a U.S. start-up biotech, for $4 million plus future payments if Daiichi brings drugs to market. Eventually, the Japanese drug maker plans to handle the biotech process on its own, but in the interim is to send antibodies and compounds to Seattle to have them combined and returned to Japan for research and development. Daiichi is interested in cancer-fighting compounds to combine with antibody drugs to make treatments more effective. (Click here for more - a subscripiton may be required